Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNNMedical - Instruments & Supplies
+$0.37 today
- Market cap
- $158.01M
- Beta
- 4.34
- P/E (TTM)
- 99.1
- EPS (TTM)
- $0.16
Volume 0.09M
Average 0.03M
NNNN Total Debt
Short-term and long-term borrowings combined.
Anbio Biotechnology Class A Ordinary SharesNASDAQ: NNNN
Total Debt · Q4 FY2025 · quarter ended Dec 2025
Total debt remains negative
Q4 FY2025 total debt was $0, compared with $0 a year earlier.
Context
- Total debt amounted to 0.0% of total assets at the end of Q4 FY2025, unchanged from a year earlier.
- Total debt increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Total Debt vs competitors
How NNNN compares with its peers on the latest reported figures
- Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
- Total debt amounts to 0.0% of total assets for NNNN, versus a peer median of 13.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $10.76B USD | -10.2% | -2.2% | 81.6% | |
| Mar 2026 | $202.93M USD | +0.1% | -3.5% | 157.4% | |
| Mar 2026 | CA$168.25M CAD | +13.7% | +0.1% | 12.8% | |
| Dec 2025 | $151.58M USD | — | — | 45.2% | |
| Mar 2026 | $138.4M USD | -1.8% | -22.5% | 13.2% | |
| Mar 2026 | $63.59M USD | +1749.6% | +69.4% | 68.1% | |
| Mar 2026 | $45.72M USD | -25.1% | +8.7% | 9.1% | |
| Mar 2026 | $2.83M USD | -91.2% | +121.4% | 0.5% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | Dec 2025 | $0 USD | — | — | 0.0% |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Feb 2026 | $0 USD | -100.0% | -33.0% | 0.0% | |
| Peer median (excluding NNNN) | — | -6.0% | -1.1% | 13.0% | |
Competitors are the stored peer set for NNNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
Intrinsic Alpha fair value
Locked
Current Price
$3.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.